Literature DB >> 29946854

Successful treatment of cytarabine-related neurotoxicity with corticosteroids, a case series.

Jennifer L Dotson1, Muhammad Omer Jamil2.   

Abstract

Neurotoxicity from high-dose cytarabine, a pyrimidine metabolite used in treatment for acute myeloid leukemia, is a known but dose-limiting toxicity which has incidences in up to 14% in patients receiving high doses of the drug. Neurologic symptoms vary but range from somnolence and ataxia to more severe complications such as seizures and even death. There are no validated treatments other than discontinuation of the drug and supportive measures. We present two cases of cytarabine-related neurotoxicity treated with corticosteroids with complete resolution of symptoms.

Entities:  

Keywords:  Acute myeloid leukemia; Cytarabine; Neurotoxicity

Mesh:

Substances:

Year:  2018        PMID: 29946854     DOI: 10.1007/s12185-018-2485-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  12 in total

1.  Cytarabine-induced neurotoxicity responding to methyl prednisolone.

Authors:  Pankaj Malhotra; Sushil Mahi; Vivek Lal; Savita Kumari; Sanjay Jain; Subhash Varma
Journal:  Am J Hematol       Date:  2004-12       Impact factor: 10.047

Review 2.  Cytarabine and neurologic toxicity.

Authors:  W J Baker; G L Royer; R B Weiss
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

Review 3.  Cancer-treatment-induced neurotoxicity--focus on newer treatments.

Authors:  Jacqueline B Stone; Lisa M DeAngelis
Journal:  Nat Rev Clin Oncol       Date:  2015-09-22       Impact factor: 66.675

4.  How I treat hematologic emergencies in adults with acute leukemia.

Authors:  Tsila Zuckerman; Chezi Ganzel; Martin S Tallman; Jacob M Rowe
Journal:  Blood       Date:  2012-06-13       Impact factor: 22.113

5.  Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman.

Authors:  J H Friedman; N Shetty
Journal:  Mov Disord       Date:  2001-05       Impact factor: 10.338

Review 6.  The toxicity of cytarabine.

Authors:  J Stentoft
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

7.  Acute cerebellar dysfunction with high-dose ARA-C therapy.

Authors:  M C Salinsky; R L Levine; J P Aubuchon; H S Schutta
Journal:  Cancer       Date:  1983-02-01       Impact factor: 6.860

8.  Cerebellar toxicity with high-dose cytosine arabinoside.

Authors:  R H Herzig; J D Hines; G P Herzig; S N Wolff; P A Cassileth; H M Lazarus; D J Adelstein; R A Brown; P F Coccia; S Strandjord
Journal:  J Clin Oncol       Date:  1987-06       Impact factor: 44.544

9.  AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.

Authors:  L H Lindner; H Ostermann; W Hiddemann; A Kiani; M Würfel; T Illmer; C Karsch; U Platzbecker; G Ehninger; E Schleyer
Journal:  Int J Hematol       Date:  2008-10-04       Impact factor: 2.490

10.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.

Authors:  R J Mayer; R B Davis; C A Schiffer; D T Berg; B L Powell; P Schulman; G A Omura; J O Moore; O R McIntyre; E Frei
Journal:  N Engl J Med       Date:  1994-10-06       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.